Breast Cancer Care & Research
|
|
- Steven Miles
- 8 years ago
- Views:
Transcription
1 Breast Cancer Care & Research Professor John FR Robertson University of Nottingham Nottingham City Hospital
2 Breast Cancer (BC) 15,000 BC deaths in the UK each year 20% female cancer deaths 5% all female deaths 89% BC deaths occur in women >50yrs
3 Structure of Cancer Care in UK SHA C A N C E R N E T W O R K PCT PCT PCT T FT T FT FT VOLUNTARY SECTOR AND HOSPICE SHA = Strategic Health Authority PCT = Primary Care Trust T = Trust Hospital FT = Foundation Trust Hospital (more independent)
4 Trusts & Foundation Trusts - Breast Units Integrated Breast Service Specialist Teams Breast Surgeons Radiologists Pathologists Plastic Surgeons Oncologists Orthopaedic Surgeons BCN Nurse Practitioners Paramedical Specialities (eg physiotherapist) Specialist Facilities Education & Training Control of Budget
5 Breast Units - Integrated Service Core Medical Members Diagnosis Primary Surgery Surgeon Radiologist Pathologist Breast Surgeon Oncologist Plastic Surgeon Pathologist Adjuvant Therapy Advanced Breast Cancer Breast Surgeon Pathologist Breast Surgeon Radiologist Oncologist Oncologist
6 Current Screening Programme 3 yearly screening for women aged Two views at all screens Single Reading
7 Has screening quality improved in the UK? SDR s all screens NHSBSP 0 93/94 95/96 97/98 99/ / /4
8 Has screening quality improved in the UK? Preoperative diagnosis in NHSBSP 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 96/97 98/99 00/ /03 preop diagnosis % by core biopsy alone
9 Has screening quality improved in the UK? Nodal staging of invasive cancer in NHSBSP 95% 90% 85% 80% nodal staging 75% 70% 96/97 98/99 00/ /03
10 Diagnosis Screening highlighted relative lack of resources for women presenting with a symptom (eg nipple discharge, lump) Screening has improved overall diagnostic facilities both screening & symptomatic
11 Structure of Cancer Care in UK SHA C A N C E R N E T W O R K PCT PCT PCT T FT T FT FT VOLUNTARY SECTOR AND HOSPICE SHA = Strategic Health Authority PCT = Primary Care Trust T = Trust Hospital FT = Foundation Trust Hospital (more independent)
12 ISSUES PCTs have multiple & competing priorities Commissioners/PCTs have a finite resource and many NSFs to fund Trusts have multiple & competing performance targets Networks have other priorities within Cancer
13 Structural Issues with The System Idea of fixed health care budget economically prudent or economically flawed? Cost control mechanism all within the box Health Care funding is now a political agenda UK is a wealthy country Implies that the cost of health care can be known before it happens Sets clinicans against each other for resources Cardiovascular Vs Cancer Lung Cancer Vs Breast Cancer
14 Structural Issues with The System More negative control mechanisms within the health care box Bureaucracy to get anything changed endless committees Focus on process rather than outcomes eg governance, audit Spending on non-front-line staff (eg governance, audit) rather than treatment (eg new drugs) New drugs have often to be found from cost savings Funding one drug for breast cancer may mean cannot fund another drug for another cancer NICE approval
15 Adjuvant Herceptin- Disease-Free Survival 100 B-31 N9831 AC TH 100 AC TH 90 AC T 87% 85% 90 AC T 87% 86% % % 66% % 68% N Events N Events AC T AC T AC TH AC TH HR=0.45, 2P=1x HR=0.55, 2P= Years From Randomization
16 B-31/N9831 Survival AC T % AC TH % 91 % 87 % N Deaths AC T AC TH HR=0.67, 2P=0.015 Years From Randomization B31/N983 1
17 Process for funding New Drugs Development of a business case/proposal Business case to Network Drugs and Therapeutics committee Recommendation to commissioners PCT process for agreeing priorities and identification of funding Authorisation/Endorsement/Implementation Audit of Compliance
18 Structure of Cancer Care in UK SHA C A N C E R N E T W O R K PCT PCT PCT T FT T FT FT VOLUNTARY SECTOR AND HOSPICE SHA = Strategic Health Authority PCT = Primary Care Trust T = Trust Hospital FT = Foundation Trust Hospital (more independent)
19 Structure of Cancer Care in UK C A N C E R N E T W O R K SHA PCT PCT PCT T FT T FT FT NICE VOLUNTARY SECTOR AND HOSPICE SHA = Strategic Health Authority PCT = Primary Care Trust T = Trust Hospital FT = Foundation Trust Hospital (more independent)
20 Breast Cancer Care in UK 2005 Performance driven Process rather than outcomes Target driven Time (eg 2 week wait ) & cost Health expenditure on breast cancer has to be justified against other diseases Processes to control spending on new drugs of developments
21 Main Research Themes Screening & Early Diagnosis Prognostic and Predictive Factors Blood Tumour Markers Autoimmunity Screening & Early Detection Antigens Diagnosis & Monitoring of MBC Therapeutics Endocrine & Growth Factor Therapies Chemotherapy Pharmacogenomics
22 Main Research Themes Screening & Early Diagnosis Prognostic and Predictive Factors Blood Tumour Markers Autoimmunity Screening & Early Detection Antigens Diagnosis & Monitoring of MBC Therapeutics Endocrine & Growth Factor Therapies Chemotherapy Pharmacogenomics
23 The average breast cancer time line Months Years MRI Mgm Symp. Detection Detection Metastasis Detected Death Primary Tumour Initiation Earliest Autoantibodies Detected 23% decrease in BC mortality. ( Mgm screening) 82% 5% Blood Antigen 70% Metastatic Cells Disseminated
24 Intensive Vs Routine Follow-up N = 1320 < 70 yrs BS & US - annual CXR - 6/12ly Compliance - 80% MFI - NS Survival - NS GIVIO Trial, 1994 N = 1243 < 70 yrs BS & CXR - 6/12ly US - None Compliance 75%-80% DFI - p<0.05 Survival - NS Del Turco et al, 1994
25
26 Absolute Reduction in Recurrence During the First 10 Years After Treatment with Tamoxifen for 5 Years EBCTCG, Lancet 1998; 351:
27 Proportion with first event (%) ATAC study Anastrozole (AN) Tamoxifen (TAM) Tam + AN P = LN(-) 61% Time to event (months) IES 031 study P = Disease free Survival Exemestane Tamoxifen 86.8%* 91.5%* LN(-) 51% ITA study P = Event-free survival Anastrozole Tamoxifen LN(-) 0% Years ABCSG 8 / ARNO 95 Anastrozole(A) Tamoxifen (T) Event-free survival (%) p-value
28
29 Antigen Research Studies Biological/molecular studies to characterise the antigens Early Diagnosis of Recurrence 5 yrs sequential collection of sera Early Intervention study pilot study UK study of standard FU Vs Early Intervention with TMs
Breast Cancer Educational Program. June 5-6, 2015
Breast Cancer Educational Program June 5-6, 2015 Adjuvant Systemic Therapy For Early Breast Cancer: Who, What and for How Long? Debjani Grenier MD, FRCPC Medical Oncologist Disclosures Advisory Board Member:
More informationThis vision does not represent government policy but provides useful insight into how breast cancer services might develop over the next 5 years
Breast Cancer 2015 Annex C Background 1. Breast cancer is the most common cancer in women in England with (not including cases of ductal carcinoma in situ (DCIS) 1 ) 39,681 new cases diagnosed in 2008
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationBreast Cancer. Presentation by Dr Mafunga
Breast Cancer Presentation by Dr Mafunga Breast cancer in the UK Breast cancer is the second most common cancer in women. Around 1 in 9 women will develop breast cancer It most commonly affects women over
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationFollow-up care plan after treatment for breast cancer. A guide for General Practitioners
Follow-up care plan after treatment for breast cancer A guide for General Practitioners This leaflet provides information for GPs on the follow-up care required by women who had breast cancer. It is for
More informationCancer patients waiting for potentially live-saving treatments in UK
Cancer patients waiting for potentially live-saving treatments in UK 29 May 2005 UK patients are waiting too long for new treatments, according to a 'Dossier of Delay' compiled by information charity CancerBACUP.
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationGuideline for the Follow Up of Patients Following Treatment for Breast Cancer
Guideline for the Follow Up of Patients Following Treatment for Breast Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Page 1 of 6 1 Scope of the Guideline This guideline
More informationCancer research in the Midland Region the prostate and bowel cancer projects
Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate
More informationRecommendations for cross-sectional imaging in cancer management, Second edition
www.rcr.ac.uk Recommendations for cross-sectional imaging in cancer management, Second edition Breast cancer Faculty of Clinical Radiology www.rcr.ac.uk Contents Breast cancer 2 Clinical background 2 Who
More informationNew Treatment Advances for Breast Cancer
New Treatment Advances for Breast Cancer Guest Expert: Lyndsay, MD Director of the Yale Cancer Center Breast Cancer Program Gina ng, MD www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center
More informationImproving survival and Clinical Trials Janyne Afseth Lecturer Edinburgh Napier University
Improving survival and Clinical Trials Janyne Afseth Lecturer Edinburgh Napier University Aims Identify the factors which may link to improved survival to clinical trials in cancer Describe some of impact
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationSurgical guidelines for the management of breast cancer
Available online at www.sciencedirect.com EJSO xx (2009) S1eS22 www.ejso.com Guidelines Surgical guidelines for the management of breast cancer Contents Association of Breast Surgery at BASO 2009 Introduction...
More informationBreast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer. Kevin R. Fox, MD University of Pennsylvania
Breast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer Kevin R. Fox, MD University of Pennsylvania Prevention of Breast Cancer Accepted treatments Tamoxifen (premenopausal
More informationLa personalizzazione terapeutica: quanto influisce l età
La personalizzazione terapeutica: quanto influisce l età PierFranco Conte University of Padova Department of Surgery, Oncology and Gastroenterology IOV Istituto Oncologico Veneto I.R.C.C.S. Breast Cancer
More informationPhyllodes tumours: borderline malignant and malignant
Phyllodes tumours: borderline malignant and malignant This booklet is for people who would like more information on borderline malignant or malignant phyllodes tumours. It describes what they are, the
More informationAdjuvant Endocrine Therapy in Breast Cancer: 2015 Update
Adjuvant Endocrine Therapy in Breast Cancer: 2015 Update Shannon Puhalla, MD Director, Breast Cancer Clinical Research Program Magee Womens Cancer Program University of Pittsburgh Cancer Institute Questions
More informationUnderstanding your pathology report
Understanding your pathology report 2 Contents Contents Introduction 3 What is a pathology report? 3 Waiting for your results 4 What s in a pathology report? 4 Information about your breast cancer 5 What
More informationGuide to Understanding Breast Cancer
An estimated 220,000 women in the United States are diagnosed with breast cancer each year, and one in eight will be diagnosed during their lifetime. While breast cancer is a serious disease, most patients
More informationInflammatory breast cancer
april 2007 information about Inflammatory breast cancer What is inflammatory breast cancer? Inflammatory breast cancer is a rare and rapidly growing form of breast cancer. Unlike other breast cancers which
More informationHormone therapy and breast cancer: conflicting evidence. Cindy Farquhar Cochrane Menstrual Disorders and Subfertility Group
Hormone therapy and breast cancer: conflicting evidence Cindy Farquhar Cochrane Menstrual Disorders and Subfertility Group The world of hormone therapy in the 1990 s Throughout the 1970s, 1980s and 1990s
More informationInvasive lobular breast cancer
Invasive lobular breast cancer This booklet is about invasive lobular breast cancer. It describes what invasive lobular breast cancer is, the symptoms, how it s diagnosed and possible treatments. Diagnosed
More informationBreast cancer research and a changing treatment pathway
Breast cancer research and a changing treatment pathway Stuart McIntosh Clinical Senior Lecturer in Surgical Oncology, QUB Consultant Breast Surgeon, BCH What is the breast surgeon s role in 2016? Surgery
More informationProstate cancer. Christopher Eden. The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing.
Prostate cancer Christopher Eden The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing. Screening Screening men for PCa (prostate cancer) using PSA (Prostate Specific Antigen blood
More informationEdinburgh Breast Unit
Edinburgh Breast Unit Treatment: Questions and Answers about Breast Cancer in South East Scotland* These questions and answers will provide an overview of the standard approaches for treating breast cancer
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationTreatment options for recurrent ovarian cancer
Treatment options for recurrent ovarian cancer There are a number of treatment options for women with recurrent ovarian cancer. Chemotherapy is the treatment most commonly offered and on occasion, surgery
More informationNew Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
More informationBreast. Patient information. cancer clinical pathway
Breast Patient information cancer clinical pathway This leaflet was written to properly inform people following breast cancer treatment plan. It doesn t replace the dialogue with healthcare staff; it rather
More informationEarly detection of breast cancer
Early detection of breast cancer Professor Denise Kendrick Division of Primary Care 1 5/26/2016 Average Number of New Cases Per Year and Age-Specific Incidence Rates per 100,000 Population Females, UK
More informationAudit. Process for managing outliers in breast cancer surgery. March 2005
Process for managing outliers in breast cancer surgery Audit March 2005 Prepared by: Australian Safety & Efficacy Register of New Interventional Procedures Surgical On behalf of: The Section of Breast
More informationHow To Use A Breast Cancer Test To Help You Choose Chemotherapy
Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat Issued: September
More informationThe best treatment Your guide to breast cancer treatment in Scotland
The best treatment Your guide to breast cancer treatment in Scotland If you are looking for information on secondary breast cancer treatment, please see Breast Cancer Now s website: breastcancernow.org/
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationThe best treatment Your guide to breast cancer treatment in England and Wales
The best treatment Your guide to breast cancer treatment in England and Wales If you are looking for information on the treatment of secondary breast cancer (also known as advanced or metastatic breast
More informationAn Update on Lung Cancer Diagnosis
An Update on Lung Cancer Diagnosis Dr Michael Fanning MBBS FRACGP FRACP RESPIRATORY AND SLEEP PHYSICIAN Mater Medical Centre Outline Risk factors for lung cancer Screening for lung cancer Radiologic follow-up
More informationEuropean Parliament resolution on breast cancer in the European Union (2002/2279(INI))
P5_TA(2003)0270 Breast cancer European Parliament resolution on breast cancer in the European Union (2002/2279(INI)) The European Parliament, having regard to Article 152 of the EC Treaty as amended by
More informationNorthampton General Hospital. Breast Multi-Disciplinary Team. Management and Clinical Guidelines
Northampton General Hospital Breast Multi-Disciplinary Team Management and Clinical Guidelines The management of breast cancer will be the same regardless of whether the diagnosis is made is a screening
More informationTheories on Metastasis: Innovative Thinking An Advocacy Perspective
Theories on Metastasis: Innovative Thinking An Advocacy Perspective Project LEAD Workshop NBCC Annual Advocacy Conference 2011 Musa Mayer AdvancedBC.org 1 The Big Question If we want to end death from
More informationFocussing on Inequalities: Variation in breast cancer outcomes with age and deprivation
Focussing on Inequalities: Variation in breast cancer outcomes with age and deprivation West Midlands Cancer Intelligence Unit ACKNOWLEDGEMENTS ACKNOWLEDGEMENTS Acknowledgements ACKNOWLEDGEMENTS The authors
More informationNational Bowel Cancer Audit Report 2008 Public and Executive Summary
National Bowel Cancer Audit Report 2008 Public and Executive Summary Prepared in association with: Healthcare Quality Improvement Partnership HQIP Association of Coloproctology of Great Britain and Ireland
More informationAll. Report BREAST CANCER. A UK analysis of all symptomatic and screen-detected breast cancers diagnosed in 2006
All BREAST CANCER Report A UK analysis of all symptomatic and screen-detected breast cancers diagnosed in 2006 West Midlands Cancer Intelligence Unit ACKNOWLEDGEMENTS ACKNOWLEDGEMENTS Acknowledgements
More informationIntroduction Breast cancer is cancer that starts in the cells of the breast. Breast cancer happens mainly in women. But men can get it too.
Male Breast Cancer Introduction Breast cancer is cancer that starts in the cells of the breast. Breast cancer happens mainly in women. But men can get it too. Many people do not know that men can get breast
More informationThere are many different types of cancer and sometimes cancer is diagnosed when in fact you are not suffering from the disease at all.
About Cancer Cancer is a disease where there is a disturbance in the normal pattern of cell replacement. The cells mutate and become abnormal or grow uncontrollably. Not all tumours are cancerous (i.e.
More informationNon-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines
Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines April 2008 (presented at 6/12/08 cancer committee meeting) By Shelly Smits, RHIT, CCS, CTR Conclusions by Dr. Ian Thompson, MD Dr. James
More informationThe Role of Clinical Practice Guidelines, Survivorship Care Plans, and Inter-sectoral Care in Cancer Rehabilitation
The Role of Clinical Practice Guidelines, Survivorship Care Plans, and Inter-sectoral Care in Cancer Rehabilitation Prof. Eva Grunfeld, MD, DPhil, FCFP Ontario Institute for Cancer Research/Cancer Care
More informationTreatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians
Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians Background The Cancer Institute New South Wales Oncology Group Lung (NSWOG Lung) identified the need for the development
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationAsk Us About Clinical Trials
Ask Us About Clinical Trials Clinical Trials and You. Our specialists and researchers are at the forefront of their fields and are leading the way in developing new therapies and procedures for diagnosing
More informationInteligentaj decidoj... Intelligente Entscheide bei der adjuvanten Therapie des Mammakarzinoms. Intelligent Questions?
Intelligente Entscheide bei der adjuvanten Therapie des Mammakarzinoms Stefan Aebi Universitätsspital Bern, Inselspital Klinik für Medizinische Onkologie und Brust /Tumorzentrum der Frauenklinik Inteligentaj
More informationBreast Cancer. Sometimes cells keep dividing and growing without normal controls, causing an abnormal growth called a tumor.
Breast Cancer Introduction Cancer of the breast is the most common form of cancer that affects women but is no longer the leading cause of cancer deaths. About 1 out of 8 women are diagnosed with breast
More informationWhat are breast cancer clinical trials?
What are breast cancer clinical trials? Contents About Us...2 Breast Cancer Institute Of Australia...3 What Are Breast Cancer Clinical Trials?...4 Why Have Clinical Trials?...5 Why Participate In A Clinical
More informationAdjuvant Therapy for Breast Cancer: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Adjuvant Therapy for Breast
More informationThe Evaluation of Cancer Control Interventions in Lung Cancer Using a Canadian Cancer Risk Management Model
The Evaluation of Cancer Control Interventions in Lung Cancer Using a Canadian Cancer Risk Management Model WK Evans, M Wolfson, WM Flanagan, J Shin, FF Liu JR Goffin, K Asakawa, N Mittmann, L Fairclough
More informationPlease see the LUCADA data manual v3.1.3, available in the downloads section
National Lung Cancer Audit Frequently Asked Questions What dataset should be used? Please see the LUCADA data manual v3.1.3, available in the downloads section What does LUCADA stand for? LUCADA stands
More informationSalisbury Lung Cancer Service (1 of 5)
Salisbury Lung Cancer Service (1 of 5) i If you need this information in another language or medium (audio, large print, etc) please contact Customer Care on 0800 374 208 email: customercare@ salisbury.nhs.uk.
More informationBreast Cancer & Treatment in ACT and Surrounding Regions QUALITY ASSURANCE PROJECT. Five-year report
Breast Cancer & Treatment in ACT and Surrounding Regions QUALITY ASSURANCE PROJECT Five-year report Community Health Pathology Southern Area Health Service ACT Health General Practitioners Nurses Social
More informationST JOSEPH REGIONAL HEALTH CENTER LUNG CANCER ANALYSIS Incidence, Diagnosis, Treatment and Survival
ST JOSEPH REGIONAL HEALTH CENTER LUNG CANCER ANALYSIS Incidence, Diagnosis, Treatment and Survival It is logical that the Cancer Program Committee choose to review the Lung Site, as Lung is the second
More informationDuctal carcinoma in situ (DCIS)
DIAGNOSIS: DCIS Ductal carcinoma in situ (DCIS) This factsheet gives information on an early form of breast cancer called ductal carcinoma in situ (DCIS). It explains what it is, how your breast is made
More informationHER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
More informationRobert Bristow MD PhD FRCPC
Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research
More informationAnalysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data
The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500
More informationBreakthrough Treatment Options for Breast Cancer
Breakthrough Treatment Options for Breast Cancer Guest Expert: Lyndsay, MD Associate Professor of Medical Oncology, Yale Cancer Center www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center
More informationTubular breast cancer
Tubular breast cancer This booklet is for people who would like more information about tubular breast cancer. It describes what tubular breast cancer is, its symptoms, how a diagnosis is made and the possible
More informationClinical Management Protocol Chemotherapy Breast Cancer. Protocol for Planning and Treatment
Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: BREAST CANCER Patient information given at each stage following agreed information pathway
More informationProportion of patients with invasive breast cancer in whom ER, PR and/or
1.1.a. Proportion of patients with invasive breast cancer in whom ER, PR and/or HER2 status assessment were performed 1.1.b. Proportion of patients with invasive breast cancer in whom systemic treatment
More informationHow TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer
How TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer Jeffrey S Tobias, Jayant S Vaidya, Frederik Wenz and Michael Baum, University College Hospital, London, UK - on behalf
More informationNOTTINGHAM UNIVERSITY HOSPITAL NHS TRUST NOTTINGHAM BREAST INSTITUTE BREAST AND OVARIAN FAMILY HISTORY GUIDELINES
NOTTINGHAM UNIVERSITY HOSPITAL NHS TRUST NOTTINGHAM BREAST INSTITUTE BREAST AND OVARIAN FAMILY HISTORY GUIDELINES GP Referrals All GP referrals for asymptomatic women with a family history of breast and/or
More informationductal carcinoma in situ (DCIS)
Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Developed by National Breast and Ovarian Cancer Centre
More informationUnderstanding ductal carcinoma in situ (DCIS) and deciding about treatment
Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Developed by National Breast and Ovarian Cancer Centre Funded by the Australian Government Department of Health and Ageing Understanding
More informationPSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening
More informationExamples of good screening tests include: mammography for breast cancer screening and Pap smears for cervical cancer screening.
CANCER SCREENING Dr. Tracy Sexton (updated July 2010) What is screening? Screening is the identification of asymptomatic disease or risk factors by history taking, physical examination, laboratory tests
More informationNon-Small Cell Lung Cancer Therapies
Non-Small Cell Lung Cancer Therapies Guest Expert: Roy, MD, PhD Assistant Professor of Therapeutic Radiology Scott, MD Assistant Professor of Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome
More informationManual for Cancer Services Breast Cancer Measures. Version 1.1
Manual for Cancer Services Breast Cancer Measures Version 1.1 VERSION CONTROL SHEET Date Version Changes Update by April 2013 1.1 Initial version Julia Hill Breast Cancer Measures GATEWAY No. 10790 - APRIL
More informationBasics and limitations of adjuvant online an internet based decision tool
Basics and limitations of adjuvant online an internet based decision tool J. Huober SAKK, Bern 31.10.2013 Univ.-Frauenklinik Ulm Integratives Tumorzentrum des Universitätsklinikums und der Medizinischen
More informationAvastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
More informationAdjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
More informationGuidelines for Management of Renal Cancer
Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated
More informationBreast Cancer. CSC Cancer Experience Registry Member, breast cancer
ESSENTIALS Breast Cancer Take things one step at a time. Try not to be overwhelmed by the tidal wave of technical information coming your way. Finally you know your body best; you have to be your own advocate.
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationCancer Association of South Africa (CANSA)
Cancer Association of South Africa (CANSA) Fact Sheet on Metastatic Breast Cancer Introduction Metastatic breast cancer is cancer that has spread beyond the breast and lymph nodes under the arm. It occurs
More informationHTA OF TRASTUZUMAB IN ADJUVANT TREATMENT FOR HER2 POSITIVE BREAST CANCER
HTA OF TRASTUZUMAB IN ADJUVANT TREATMENT FOR HER2 POSITIVE BREAST CANCER Karianne Johansen, PhD, Senior Advisor, Torbjørn Wisløff, Researcher Inger Natvig Norderhaug, Research Director Norwegian Health
More informationLung Cancer Multidisciplinary Meeting Toolkit. National Lung Cancer Working Group
Lung Cancer Multidisciplinary Meeting Toolkit National Lung Cancer Working Group September 2014 Contents Introduction 1 Multidisciplinary meetings 1 Toolkit for implementing high-quality lung cancer MDMs
More informationWisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics
Wisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics In Situ Breast Cancer in Wisconsin INTRODUCTION This bulletin provides information
More informationChemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationMetastatic Breast Cancer...
DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a
More informationGenomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More informationSupportive Care For Patients With High-Grade Glioma (primary brain tumours) Dr Susan Catt & Professor Lesley Fallowfield
Supportive Care For Patients With High-Grade Glioma (primary brain tumours) Dr Susan Catt & Professor Lesley Fallowfield Partners Mr Giles Critchley Consultant Neurosurgeon Hurstwood Park Neurological
More informationGuidelines for Cancer Prevention, Early detection & Screening. Prostate Cancer
Guidelines for Cancer Prevention, Early detection & Screening Prostate Cancer Intervention Comments & Recommendations For primary prevention, it has been suggested that diets low in meat & other fatty
More informationFact sheet 10. Borderline ovarian tumours. The difficult cases. What is borderline ovarian cancer (BOC)?
For this reason, some doctors prefer the term borderline ovarian tumour rather than borderline ovarian cancer. Fact sheet 10 Borderline ovarian tumours We, Ovacome, are a support network for people affected
More informationTreating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer
Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone
More informationInova. Breast Care Institute
Inova Breast Care Institute At the Inova Breast Care Institute, our commitment is to provide expert care for you, every step of the way. Our multidisciplinary team of more than 80 experts provides a full
More informationBreast Cancer Follow-Up
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Breast Cancer Follow-Up Breast Cancer Follow-Up Version 2002: Thomssen / Scharl Version 2003 2009: Bauerfeind / Bischoff /
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationTrastuzumab (Herceptin ) for patients with metastatic breast cancer
JULY 2007 Incorporates published evidence to November 2006 INFORMATION ABOUT Trastuzumab (Herceptin ) for patients with metastatic breast cancer This information has been developed to help you understand
More informationTumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
More informationMANCHESTER Lung Cancer Screening Program Dartmouth-Hitchcock Manchester 100 Hitchcock Way Manchester, NH 03104 (603) 695-2850
LEBANON Lung Cancer Screening Program One Medical Center Drive Lebanon, NH 03756 (603) 650-4400 (866) 966-1601 Toll-free cancer.dartmouth.edu/lungscreening MANCHESTER Lung Cancer Screening Program Dartmouth-Hitchcock
More information